Prediction of immune-related adverse events induced by immune checkpoint inhibitors with a battery of autoantibodies

We hypothesized that the presence of autoantibodies may predict the risk of developing immune-related adverse events (irAEs) in patients with cancer receiving immune checkpoint inhibitors (ICIs). We aimed to assess the diagnostic performance of a battery of autoantibodies to predict irAEs in patients with cancer receiving ICIs.